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Carrier screening is a genomic technology that is used to identify individuals who are
carriers of autosomal recessive conditions. Despite published recommendations, the majority of
male partners do not complete carrier screening after their female partner is identified to be a
carrier. Previous studies have examined reasons why women elect or decline carrier screening,
but there have been few published studies that examine factors that influence a male partner’s
decision to elect or decline carrier screening, particularly when the female has been identified as
a carrier. The aim of the study was to determine the factors that influence the uptake of carrier
screening in male partners at several clinics within an academic medical center. Data was
ascertained via a novel survey. Of the 98 patients included in the analysis, more than half of the
male partners did not attend the initial counseling session (57/98, 58%), but the partner being
present at the initial genetic counseling session was significantly associated with his uptake of
carrier screening (p=0.001). The only other significant factor included the male partner placing
increased importance on wanting to be able to plan for the future (p= 0.006). Of the couples
where the female was identified to be a carrier (n=21), 18 (86%) of them indicated that the male
partner would pursue screening if the female screened positive. However, only 5 males
ultimately completed carrier screening (28%). The study confirms that despite published
recommendations and original intentions of the patient and/or her partner to follow such
recommendations, the majority of male partners are not completing carrier screening after their
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female partner screens positive for an autosomal recessive condition. Future studies should
examine barriers to partner screening and investigate methods to increase the utility of prenatal
carrier screening.
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INTRODUCTION
Carrier screening is a genomic technology that is used to identify individuals who are
carriers of autosomal recessive conditions. If an individual is found to be a carrier of an
autosomal recessive condition, it typically does not have any direct clinical impact on the
individual’s health (1). Rather, knowing this information can be utilized for family planning
decisions and/or postnatal preparation. If both partners are found to be carriers of the same
condition, there is a 25% chance that their offspring would be affected with the condition, and a
variety of reproductive options both prior to and during an ongoing pregnancy could be pursued
to either minimize or better understand this risk (1, 2).
The American College of Obstetricians and Gynecologists (ACOG) recommends that
information about carrier screening be offered to all pregnant women, but states that ideally,
carrier screening should be offered prior to pregnancy, as this allows for more reproductive
options to be considered (1, 3). Additionally, ACOG recommends that when an individual is
found to be a carrier of an autosomal recessive condition, their reproductive partner should
pursue carrier screening to clarify the couple’s reproductive risk (1, 2, 4). Concurrent screening
can be considered depending on gestational age, partner availability, and patient preference (1,
2, 4).
Since the purpose of carrier screening is to inform couples about potential reproductive
outcomes, the clinical utility of carrier screening relies on the availability and willingness of
both the patient and her male partner to elect and complete carrier screening (1). Previous
studies have examined reasons that influence a woman’s decision to elect or decline carrier
screening (3, 5-10), but there have been few published studies that examine factors that
influence a male’s decision to pursue carrier screening, particularly when an increased risk for
an autosomal recessive condition has been established (11). A retrospective study by Giles
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Choates et al. found that only 38% of males completed carrier screening after their female
partner was found to be a carrier of an autosomal recessive condition (12). Male partner uptake
of carrier screening was primarily associated with lower parity and younger gestational age of
the female patient, but more specific factors affecting this low rate could not be ascertained by
the authors due to the retrospective nature of the study (12). This incomplete follow-through
may ultimately undermine the impact of carrier screening on patient management and risk
assessment, and likely is a source of wasted healthcare dollars and provider time. To have a
better understanding of the clinical utility of carrier screening, knowledge of more specific
factors that influence a male partner’s decision to elect carrier screening is imperative.
Exploring these factors may provide insight into barriers to male partner screening, which can
then allow for improved clinical utility. This study thus aimed to determine what factors
influence the uptake of carrier screening in reproductive couples and to identify potential
deterrents to uptake of carrier screening in male partners using a survey tool, particularly when
an increased risk for an autosomal recessive condition has been established.
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METHODS
Study Design and Participants
Individuals were recruited to participate in this prospective study from four UTHealth
Maternal Fetal Medicine (MFM) practices in Houston, TX between July 31, 2019 and January
31, 2020. Participants were eligible for the study if they met with a prenatal genetic counselor
for either prenatal or preconception genetic counseling, were over 18 years of age, Englishspeaking, not known to be a carrier of an autosomal recessive disorder, and elected carrier
screening during the genetic counseling appointment. Individuals who previously had negative
carrier screening were eligible as long as they elected a panel with additional conditions. The
carrier screening practices of the UT MFM clinics have been previously described (12).
Traditional carrier screening was defined as panels that include autosomal recessive conditions
recommended by ACOG (cystic fibrosis, spinal muscular atrophy, hemoglobinopathies, TaySachs disease, Canavan disease, familial dysautonomia, Bloom syndrome, Fanconi anemia,
Gaucher disease, Niemann-Pick disease, mucolipidosis type IV, and hexosaminidase A
deficiency.) Expanded carrier screening is defined as panels that include autosomal recessive
conditions beyond those recommended by ACOG (1, 12).
The participant ascertainment and survey distribution scheme are outlined in Figure 1.
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Figure 1: Participant Ascertainment and Survey Distribution Scheme

Women who elected to participate in the study are referred to as “patient” and their male
reproductive partner are referred to as “partner.” Individuals who attended the genetic
counseling session alone, elected carrier screening, and elected to participate in the study, were
asked to complete a novel survey asking about their intent to notify their partner about their
carrier screening, their intent to ask their partner to pursue carrier screening if the patient was
found to be a carrier of a condition, and factors that influenced the patient’s decision to elect
carrier screening, presented via a Likert measure. If a patient presented to the genetic counseling
appointment with her partner, both the patient and her partner were invited to complete a novel
survey that asked about factors impacting their decision to elect either simultaneous or
sequential carrier screening presented via a Likert measure, depending on their testing decision.
4

Couples who elected sequential testing were also asked about their intent to get the partner
screened if the patient was found to be a carrier of an autosomal recessive condition. Selfreported and/or partner-reported demographic data was collected for all groups.
Patients who were found to be a carrier of at least one autosomal recessive condition
were sent an electronic follow-up survey if her partner did not elect simultaneous testing. The
survey asked patients if they communicated the result to their partner, if their partner elected
carrier screening, and about factors that the patients thought had an impact on their partner’s
decision to elect or decline carrier screening. After completion of the electronic survey, patients
were sent an additional electronic survey for their partner to complete. The electronic survey
asked partners if they ultimately elected carrier screening and asked about factors that
influenced their decision to elect or decline carrier screening presented via a Likert measure.
This study was approved by the UTHealth Institutional Review Board (#HSC-MS-19-0475).
Data Analysis
Descriptive statistics were used to characterize the participants. Variables of interest
were compared using Mann-Whitney-U test, t-test, and Fisher’s exact test as appropriate. The
male partners’ demographic characteristics were primarily used in the data analysis. Variables
of interest included partner age, gestational age at the time of the patient’s screening, the
partner’s education level, whether this was the couple’s first child together, the partner’s
insurance, the partner’s race/ethnicity, whether the couple identified as the same race, whether
the partner was present at the initial genetic counseling session, and whether the partner elected
carrier screening. Variables of interest were compared between partners who elected carrier
screening and those that did not. Additionally, Likert responses between the patient and her
partner as well as between partners who did and did not elect carrier screening were compared
using Wilcoxon signed-rank test and Mann-Whitney-U test, respectively. Fisher analyses were
5

performed to determine if disease severity, determined using a modified version of the disease
severity algorithm developed by Lazarin et al. or the presence of the disorder on the Texas
Newborn Screen (NBS) impacted uptake of partner carrier screening (13). Due to the small
sample size, Lazarin’s algorithm was modified from four disease severity categories to two. The
categories profound and severe were grouped together and moderate and mild were grouped
together. Statistical analyses were conducted using Stata (StataCorp, College Station,
Texas) with statistical significance set at p <0.05. The interquartile range (IQR) is presented as
the 25th to 75th percentile. Given the low sample size of the electronic survey respondents, we
present some descriptive data without statistical analysis.
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RESULTS
Participant Enrollment and Carrier Screening Uptake
Of the 291 patients who elected carrier screening, 101 (34.7%) were enrolled in the
study. Three individuals were excluded from analysis, due to cancelled test order, sample
failure, and pregnancy loss. Of the 98 patients who were analyzed, 57 (58.2%) attended the
initial genetic counseling session without their partner. The majority of patients were
multigravida (n= 64, 65.3%) and presented to genetic counseling during the first trimester of
pregnancy (n= 82, 83.7%). Patient characteristics are shown in Table 1.

Table 1: Characteristics of Patients Enrolled in the Study
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The type of carrier screening panel the patient elected at the initial genetic counseling
appointment was relatively evenly split between traditional carrier screening panels (52%) and
expanded carrier screening panels (48%). In total, 30 (30.6%) women were identified to be a
carrier of at least one autosomal recessive condition. Twenty-one of these patients either
attended the initial genetic counseling session alone or with a partner that did not elect
simultaneous screening. The conditions for the 21 patients are described in Table 2.

Table 2: Patients who were Identified as Carriers of Autosomal Recessive Conditions
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A total of 19 (19.4%) partners elected carrier screening. Among partners who attended
the initial genetic counseling appointment, 14/41 (31.4%) elected simultaneous carrier screening
and 2/7 (28.6%) returned for carrier screening after the female patient was identified as a carrier.
When the patient attended the initial genetic counseling session alone and was identified as a
carrier, 3/14 (21.4%) partners returned to complete their carrier screening. Of the 21 patients
that either attended the initial genetic counseling session alone or with a partner that did not
elect simultaneous screening, 18 (85.7%) of the patients or partners indicated on the survey that
they would pursue carrier screening for the partner if the patient was identified to be a carrier.
However, only 5 of the 18 (27.8%) ultimately followed through with screening.
For couples who underwent sequential testing, the average number of days between the
patient’s result disclosure session and the partner’s blood draw was 53.3 days (n=3, SD 43.8
days) for those partners who were not present at the initial genetic counseling session, and 14
days (n=2, SD 0 days) for those who were present at the session.
Two couples, who both elected simultaneous screening, were determined to be carriers
of the same condition. One couple was known to be consanguineous. No other at-risk couples
were identified. Figure 2 illustrates patient and partner carrier screening uptake.
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Figure 2: Patient and Partner Carrier Screening Uptake

Demographic Factors Associated with Partner Carrier Screening Uptake
Demographic characteristics for the partners are presented in Table 3.
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Table 3: Characteristics of Partners Enrolled in the Study

The majority of partners reported having less than a college degree (n= 51, 57.3%),
having private insurance (n=61, 68.5%), being the same race/ethnicity as their partner (n=75,
76.5%), and reported that it was their first child with the patient (n=60, 61.2%). The partner’s
attendance at the initial genetic counseling session was the only significant difference observed
between partners who did and did not elect carrier screening (p=0.001). If the partner was
present at the initial genetic counseling session, the rate of carrier screening uptake was 39%
(n=16/41) compared to the overall partner carrier screening uptake rate of 19.4%. Additionally,
while no statistically significant differences were observed in the partner’s race/ethnicity
between partners who did and did not elect carrier screening, six (50%) partners that reported
11

Asian race elected carrier screening and accounted for 31.6% of the entire partner population
that elected carrier screening. Other partner characteristics including education level, type of
insurance, number of previous children with the patient, and gestational age of the patient were
not significant predictors of male carrier screening uptake.
Partner Likert Measure Responses
Overall, the most commonly reported reasons in the carrier screening decision-making
process for partners were “I like to know as much information as possible” (92.1% selecting
moderately or extremely important), “I want to know if I am at risk of having a child with an
autosomal recessive condition” (86.5 % selecting moderately or extremely important), and “I
want to be able to plan for the future” (84.2% selecting moderately or extremely important).
Factors including the genetic counselor or doctor recommending carrier screening, affordability
of carrier screening, and the patient wanting the partner to be screened, were not reported as
being as influential in the decision-making process (Figure 3).

Figure 3: Partner Likert Responses
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We were interested to determine if partners who elected carrier screening ranked any
factors as being more influential than partners who did not elect carrier screening. The Likert
distribution was significantly different for “I want to be able to plan for the future” between the
two groups. The respondents that elected carrier screening were more likely to assign moderate
or extreme importance to this factor (n=16/16, 100%) compared to those that did not elect
carrier screening (n=16/22, 72.8%), (p=0.006). Similar trends of higher levels of importance in
decision making were assigned to “I am worried about having a child with a genetic condition,”
“The genetic counselor recommended that I get testing,” and “I plan to use this information to
make decisions about the pregnancy” by the partners who elected carrier screening (n= 13/16,
82%; n=8/15, 53%; and n=12/16, 75%, respectively) compared to those that did not elect carrier
screening (n= 12/21, 57.1%; n=6/20, 30%; and n=12/22, 54.5%, respectively.) However, these
trends failed to reach statistical significance (p = 0.068, p = 0.093, and p=0.109, respectively.)
(Table 4).
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Table 4: Partner Likert Responses of Partners that Elected Versus Did Not Elect Carrier
Screening (CS)

Likert responses were also compared between partners who attended the initial session
and did not elect carrier screening and those that elected simultaneous carrier screening to
determine if factors differed between these two groups. The Likert distribution was significantly
different for “I was worried about having a child with a genetic condition” between the two
groups. The respondents that elected simultaneous carrier screening were more likely to assign
moderate or extreme importance to this factor (n=12/13, 92%) compared to those that did not
elect simultaneous carrier screening (n=13/24, 54%), (p=0.018). Respondents that elected
simultaneous carrier screening were also more likely to assign moderate or extreme importance
to the factor “I want to be able to plan for the future” (n=13/13, 100%) compared to those that
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attended the initial genetic counseling session, but did not elect simultaneous carrier screening
(n=19/25, 76%), (p=0.007). Additionally, Likert distribution was significantly different for “The
genetic counselor recommended that I get testing” between the two groups. The respondents
that elected simultaneous carrier screening were more likely to assign moderate or extreme
importance to this factor (n=7/12, 59%) compared to those that were present at the initial
genetic counseling session but did not elect simultaneous carrier screening (n=7/23, 31%),
(p=0.04) (Table 5).

Table 5: Partner Likert Responses of Partners that Elected Simultaneous Carrier Screening (CS)
Versus Did Not Elect Simultaneous Carrier Screening
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Paired Patient and Partner Couple Likert Measure Responses
We explored that agreement between patient and partner responses, which we
hypothesized may influence testing decisions. No significant differences between patient and
partner Likert responses were identified when analyzing both couples where the partner elected
carrier screening and those where partners did not elect carrier screening. Overall, agreement
between the patient and the partner ranged from 30.6% (11/36) to 70.3% (26/35). Patients were
more likely to assign a higher level of importance to the factor “I want to be able to plan for the
future” compared to their male partners, however, this trend failed to reach statistical
significance (p = 0.057). Further analysis of the paired Likert responses from couples where the
partner did not elect carrier screening indicated that patients in this cohort assigned a higher
importance to the factor “I want to be able to plan for the future” compared to their male
partners (p=0.02). Alternatively, there was not a significant difference in level of importance
assigned to this factor between couples in which the partner elected carrier screening (p= 0.564).
Impact of Disease Severity and Presence on Newborn Screen on Uptake of Carrier Screening
We hypothesized that the severity of the disease detected on the patient’s carrier
screening would affect the likelihood of partner testing. Therefore, we classified diseases using
a modified version of the disease severity algorithm developed by Lazarin et al. Disease severity
was not associated with partner carrier screening uptake (p=0.550) (13).
Additionally, we hypothesized that partners may be less likely to pursue screening if the
condition was screened for via the Texas Newborn Screening program. The presence of the
condition on the Texas Newborn Screen was not associated with partner carrier screening
uptake (p=0.344).
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Electronic Surveys
Electronic surveys were sent to the 21 patients who were found to be a carrier of an
autosomal recessive condition whose partner did not elect simultaneous screening. Four patients
(19%) completed the electronic survey. One patient’s partner elected carrier screening and
completed his separate online survey; three partners neither elected carrier screening nor
completed his online survey. The three patients whose partners did not pursue carrier screening
were asked to indicate on a Likert scale the extent to which they thought certain factors
contributed to their partner’s decision to decline carrier screening. Two out of three (66.7%) of
respondents indicated extreme importance for the following factors: “I do not think he is a
carrier of the condition” and “He does not think he is a carrier of the condition.” One patient
also indicated extreme importance to “The results would not influence the management of the
pregnancy,” while the other two patients indicated that factor was not important at all.
Additionally, one respondent indicated that her partner did not get carrier screening because
“Further testing not done because carrier result would only impact male child and sex of baby
was determined female.” This participant was a carrier of a cystic fibrosis poly T tract
polymorphism that may lead to infertility in males but is otherwise not considered to be diseasecausing. None of the 3 patients indicated that they believed factors such as religious beliefs, not
having a family history of the condition, the partner being scared that he is a carrier of the
condition, or the partner forgetting to go in for testing had any impact on their partner’s decision
to decline carrier screening.
The one partner that completed the electronic survey indicated that he elected carrier
screening because “The test was affordable/my insurance covered it” as the factor that had the
biggest impact on him electing carrier screening. He also indicated extremely high importance
to the factor “It was convenient to send my sample in for testing.”
17

DISCUSSION
Uptake of sequential carrier screening for males whose female reproductive partner was
identified to be a carrier of a condition was 23.8%. This rate is similar to what has been
previously reported in the literature (12). The results of the study continue to suggest that
despite recommendations put forth by ACOG (1, 5), the majority of male partners are not
completing carrier screening, even when the patient is found to be a carrier for an autosomal
recessive condition, and even if the patient or partner stated that it was their intention to have
this performed.
While previous studies have examined reasons why women elect or decline carrier
screening, our study differs as it focuses on assessing specific factors that impact a male
partner’s decision to elect carrier screening. Previous studies have assessed factors that impact a
woman’s decision to pursue carrier screening and found that doctors recommending carrier
screening, perception of certain autosomal recessive conditions as severe diseases, and wanting
to prepare seem to influence decision making (7-9). Our study examined similar factors in the
male population and found that influential factors in the decision-making process included
wanting to know information, wanting to be able to plan for the future, and wanting to know if
their child would have an autosomal recessive condition. Additionally, partners that elected
carrier screening assigned more importance to “I want to be able to plan for the future” than
partners that did not elect carrier screening. While not statistically significant, partners who
elected carrier screening tended to assign more importance to the factors “I plan to use this
information to make decisions about the pregnancy” and “I was worried about having a child
with a genetic condition,” compared to partners that did not pursue carrier screening. Our study
suggests that individuals often elect carrier screening because they want to be able to plan for
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the future, while those who decline may be less inclined to use the information to inform
choices about the pregnancy.
Other earlier studies in female prenatal and preconception patients revealed that factors
that influence a woman’s decision to decline carrier screening include having no family history
of a genetic condition, perception that the chance to be a carrier is small, not planning to make
pregnancy decisions based on the results, not wanting to know the information, lack of interest,
and potential causes of worry or anxiety (5, 6, 8-10). Similarly, for those that completed our
electronic survey, the belief that the partner was not a carrier of the patient’s condition seemed
to influence the couple’s decision to decline his screening. These perceptions held by the patient
and/or her partner make us wonder that, despite counseling on the carrier frequency and/or
couple’s empiric reproductive risk for a particular condition, personal perceptions of risk and
the notion that “it’s never going to be me” (10) may be the most important misconception to
correct to improve partner uptake.
Previous studies looking at uptake of carrier screening in the male partner population
found that partner uptake of carrier screening was influenced by gestational age and parity (12).
Our study examined partner demographic characteristics, including gestational age at the time of
the initial genetic counseling visit and number of children with the current partner, which was
used as a proxy for parity, and did not find that either of those factors were significant predictors
of carrier screening uptake in partners. Differences between our findings and existing literature
may be due to sample ascertainment, as previous data was acquired via chart review, while this
study was a survey. Additionally, we found no significant difference in uptake across partner
education level, partner race/ethnicity, partner insurance type, or partner age, suggesting that
partner uptake is uniformly lacking across all demographic groups. Other factors that have
previously been hypothesized to play a role in partner carrier screening uptake including
19

affordability and convenience of sample collection were not determined to be an influential
factor in this study (12). Furthermore, partner uptake in potentially at-risk couples was not
predicted by severity of the condition that the patient was found to be a carrier for, or the
presence of the condition on the Texas Newborn Screen.
What we did find was that partner screening was significantly higher among those who
attended the initial genetic counseling appointment. We speculate that partners who are engaged
in the initial conversation about carrier screening likely have a better understanding of carrier
screening, including the recommendation to pursue carrier screening if the patient is identified
to be a carrier of a condition. Previous literature has documented that lack of interest in carrier
screening may be linked to lack of awareness and knowledge (14, 15).
Additionally, we found that the partner’s attendance at the genetic counseling session
may reduce the wait time between result disclosure of the patient’s positive result and the
partner’s sample collection for at-risk couples who elect sequential testing. Partners who
attended the genetic counseling session on average waited 14 days between the patient’s initial
result disclosure and partner sample collection (n=2). Partners who did not attend the genetic
counseling session on average waited 53.3 days between the patient’s initial result disclosure
and partner sample collection (n=3). Although this was a small sample size, partners who
attended the initial genetic counseling session received final results, and thus risk clarification,
sooner than partners who did not attend the initial genetic counseling session. However, this
may reflect ascertainment bias, as partners that attend a genetic counseling session may be
inherently more engaged and interested in this aspect of the pregnancy. If the goal is to increase
uptake of carrier screening in the partner population, and better adhere to time constraints often
placed on decision-making during pregnancy, measures such as encouraging partners to attend
obstetric or genetic counseling appointments with the patients may be beneficial.
20

Differences in patient and partner views may also influence uptake of partner carrier
screening. Our study observed that patients want to use information from carrier screening to
plan for the future more than their partners who did not elect carrier screening. This discrepancy
in the perceived value of carrier screening among couples may be partially responsible for the
lack of follow-up of carrier screening by the male. Previous studies were unable to comment on
whether males not completing carrier screening was patient- or partner-driven (12). However,
this difference in perceived importance about planning for the future may suggest that another
barrier to male partner carrier screening completion lies with the male’s perceptions about the
value of or need for carrier screening itself. When possible, it may be fruitful to explore both the
patient and the partner’s views on carrier screening during pre-test counseling in order to
uncover any potential discrepancies in priorities prior to testing. However, in order to explore
these views, the partner’s attendance is required, which has already been determined by this
study to be associated with increased carrier screening uptake.
The study confirmed that there is a discrepancy between guideline recommendations and
uptake of carrier screening by male partners, which ultimately depreciates the overall utility of
carrier screening. From this cohort, a complete assessment could not be provided to over half of
potentially at-risk couples. Alternatively, from this cohort, only 2 at-risk couples were identified
by carrier screening, one of which was a consanguineous couple whose a priori risk to be
carriers of the same autosomal recessive condition was expected to be higher than the general
population. Previous studies have highlighted the burden on healthcare costs and provider time
caused by the current landscape of carrier screening (12, 14, 16). This study again supports that
the utility of carrier screening is hindered by incomplete uptake by male partners. Debate exists
regarding the best way to implement carrier screening and some have argued that offering
screening only to couples, rather than to individuals, maximizes clinical utility and minimizes
21

provider time (14, 17). We found that partners that attended the initial genetic counseling
appointment and elected simultaneous carrier screening were more likely to assign moderate or
extreme importance to the factor “The genetic counselor recommended that I get testing”
compared to the partners that attended but did not elect simultaneous genetic counseling
(p=0.04). This suggests that some genetic counselors may be promoting simultaneous carrier
screening due to its acknowledged benefits. Further exploration of this topic including the cost
benefit or risk of promoting simultaneous carrier screening is warranted.
Additionally, future practices and guidelines may consider advocating for the partner’s
presence at medical appointments when possible. It is important to acknowledge that some
women may not have a reproductive partner that is available to pursue testing due to a variety of
reasons including lack of adequate insurance, not being involved in the pregnancy, or unclear
paternity. Alternatively, presence of the partner may be a luxury that some couples simply
cannot afford, such as in cases where the male cannot be excused from work to attend the
patient’s appointment(s). With the expansion of genetic screening availability and affordability,
the hope would be that testing could transcend these adversities, but if carrier screening hinges
on partner attendance, this may highlight an example of health disparity for some families.
Barriers to clarifying reproductive risk due to lack of paternal testing may be reduced as
technology continues to advance. Recently, a non-invasive screen that tests cell-free DNA
(cfDNA) for a select number of autosomal recessive conditions was introduced to the United
States market. The screen is able determine if a female is a carrier for a small subset of
conditions and reflexes to analyze cell-free DNA to determine if the pregnancy is at a high or
low risk to be affected with the autosomal recessive condition, if the patient is identified to be a
carrier (18). cfDNA screening for recessive conditions has been available in the United
Kingdom and other countries for several years. While traditional carrier screening methods
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remain standard of care, new carrier screening technology may be able to provide more accurate
risk assessments for women whose partner is not able to pursue screening.
Strengths and Limitations
This study contributes valuable findings to a currently limited body of literature that is
working to elucidate factors that impact uptake of carrier screening of males in the prenatal and
preconception patient population. A strength of this study was that it was conducted at an
academic medical institution that serves a demographically diverse population. The population
studied was diverse in both racial and socioeconomic makeup and thus, the results may be
generalizable to the entire population.
Limitations to this study include its small sample size and use of novel surveys that have
not been validated. Additionally, an aim of this study was to identify factors that impact uptake
in at-risk males whose female partner was found to be a carrier of an autosomal recessive
condition. Due to low uptake of the partner follow-up survey, we were not able to adequately
analyze this aim. Of the 21 couples where the patient was found to be a carrier, 18 (85.7%)
indicated that they would pursue carrier screening for the partner if the patient was identified to
be a carrier. However, only 5 partners ultimately followed through with the testing. Due to low
uptake of the follow-up survey we were not able to capture how the decision-making process
changed over time. In order to truly understand what is driving the decision-making process for
at-risk couples, it is necessary to collect complete data from couples after one partner has been
identified to be a carrier.
Future Directions
Future studies should explore factors that impact uptake of carrier screening in male
partners whose female reproductive partner is known to be a carrier of an autosomal recessive
condition. Focusing on carrier screening uptake in male partners of at-risk couples may provide
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more robust information about factors that influence uptake in situations where ACOG
guidelines are more immediately pertinent (1).
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